Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
| Autor: | Caterina Confente, Julien Pierrard, Guillaume Grisay, Emmanuel Seront |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Urologic Neoplasms medicine.medical_specialty Combination therapy medicine.medical_treatment Immune checkpoint inhibitors Clinical Decision-Making Antineoplastic Agents Targeted therapy 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans Pharmacology (medical) Molecular Targeted Therapy Treatment Failure Neoplasm Metastasis Immune Checkpoint Inhibitors Neoplasm Staging Urothelial carcinoma business.industry Disease Management Immunotherapy Immune Checkpoint Proteins Prognosis Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Retreatment Biomarker (medicine) Disease Susceptibility business |
| Zdroj: | Current Treatment Options in Oncology. 22 |
| ISSN: | 1534-6277 1527-2729 |
| DOI: | 10.1007/s11864-020-00799-9 |
| Popis: | Immune checkpoint inhibitors have importantly improved the outcome of patients with urothelial carcinoma. Different immune checkpoint inhibitors are currently approved and used in first- and second-line setting. The multiple agents currently approved in these setting make the choice sometimes difficult for clinicians. Furthermore, only a minority of patients present drastic response and long-term benefit with current immunotherapy. In this review, we describe the current use of immunotherapy in urothelial carcinoma but we also highlight the new strategies of treatment involving immune checkpoint inhibitors; we describe the place of immunotherapy with chemotherapy, targeted agents, and anti-angiogenic agents, incorporating the recent results presented at ASCO 2020. This review explores also the different action mechanisms of immune checkpoint inhibitors and the molecular rational to evaluate these agents in other strategies, such as maintenance and salvage strategies. The new advances in biomarker development are also presented. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink